Too Much Success for Generics? GPhA’s Neas Defends Hatch-Waxman
This article was originally published in RPM Report
Executive Summary
Newly installed GPhA CEO Ralph Neas has a lot to juggle these days on Capitol Hill, between drug shortages and user free agreements for generics and biosimilars. But one thing Neas wasn’t expecting was a threat to Hatch-Waxman. Has the generic drug industry become too successful for its own good?